Isolation and identification of major metabolites of rifalazil in mouse and human
- 1 January 1999
- journal article
- clinical trial
- Published by Taylor & Francis in Xenobiotica
- Vol. 29 (11) , 1073-1087
- https://doi.org/10.1080/004982599237967
Abstract
1. Three metabolites of rifalazil have been isolated from dog urine and identified as 25-deacetyl-rifalazil, 30-hydroxy-rifalazil and 25-deacetyl-30-hydroxy-rifalazil. In the current study major metabolites of rifalazil in mouse and human were isolated and identified, and their antimicrobial activities determined. 2. Urinary excretion of rifalazil and its metabolites in six mouse strains, CD-1 (ICR), BALB/c, C57BL/6, C3H/He, DBA/2 and CBA/J, was examined. Two major metabolites were detected in mouse urine obtained after several oral doses, and the proportion of rifalazil metabolites against total urinary excretion varied over a 2-fold range (4.8-8.7%) in the different mouse strains. 3. One of two major metabolites in mouse urine was 25-deacetyl-rifalazil and the other was unknown: it was isolated from mouse urine and identified by ms and 1H- and 13C-nmr as 32-hydroxy-rifalazil. 4. In human, two major metabolites of rifalazil were detected in urine obtained after administration of a single oral dose. These metabolites were also produced by incubation of rifalazil with pooled human liver microsomes, and identified by lc/ms and lc/ms/ms as 25-deacetyl-rifalazil and 32-hydroxy-rifalazil. 5. The antimicrobial activities of 32-hydroxy-rifalazil against Gram-positive bacteria and mycobacteria were similar with those of the parent compound.Keywords
This publication has 7 references indexed in Scilit:
- In vitrometabolism of a rifamycin derivative by animal and human liver microsomes, whole blood and expressed human CYP3A isoformXenobiotica, 1996
- Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine modelAntimicrobial Agents and Chemotherapy, 1994
- Activities of the benzoxazinorifamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophagesAntimicrobial Agents and Chemotherapy, 1994
- In vitro and in vivo antibacterial activities of KRM-1648 and KRM-1657, new rifamycin derivativesAntimicrobial Agents and Chemotherapy, 1994
- High-performance liquid chromatographic determination of 3′-hydroxy-5′-(4-isobutyl-1-piperazinyl)benzoxazinorifamycin (KRM-1648) and its deacetyl metabolite in plasma, whole blood, urine and tissue samples in ratsJournal of Chromatography B: Biomedical Sciences and Applications, 1994
- Synthesis and Biological Activity of 3'-Hydroxy-5'-aminobenzoxazinorifamycin Derivatives.CHEMICAL & PHARMACEUTICAL BULLETIN, 1993
- In vitro antimicrobial activity of benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex, determined by the radiometric methodAntimicrobial Agents and Chemotherapy, 1993